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utilities for pazopanib and placebo were from PALETTE. Lacking a connected evi-
dence network, estimates of relative effectiveness for trabectedin and ifosfamide
were from an unadjusted indirect treatment comparison vs. pazopanib. Costs were
from NHS reference costs and other published sources. RESULTS: Compared with
placebo, pazopanib is estimated to increase QALYs by 0.130 and costs by £8,072; the
incremental cost effectiveness ratio (ICER) for pazopanib vs. placebo is estimated to
be £63k/QALY gained. For most parameters, the ICER changed 30% with /50%
changes in the parameter value. Compared with trabectedin and ifosfamide, pazo-
panib provides equal or more QALYs at a lower cost. CONCLUSIONS: From a UK
health care system perspective, pazopanib may not be cost-effective vs. placebo in
patients with advanced/metastatic STS based on criteria typically used to evaluate
therapies in the UK. Pazopanib may be cost-effective vs. trabectedin and ifosf-
amide, although there is substantial uncertainty associated with these compari-
sons.
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OBJECTIVES: Eurtact trial was the first randomized phase III trial evaluating effi-
cacy and safety of erlotinib vs chemotherapy in the first-line treatment of EGFR
mut Caucasian patients. This trial showed an increase in the median PFS of 4,5
months with erlotinib vs chemotherapy. Based on this study, we aimed to assess
the cost-effectiveness of erlotinib versus platinum based chemotherapy in the
first-line treatment of advanced NSCLC patients with activating EGFR mutations.
METHODS: A health economic cost-effectiveness analysis was developed incorpo-
rating a Markov model simulating the evolution of a cohort of advanced NSCLC
patients with activating EGFR mutations. Three health states were included: Pro-
gression Free Survival (PFS), Progression and Death. The time horizon was 7 years.
Outcomes were life years gained (LYG). Resource utilization related to each health
state was estimated by a Spanish Expert Panel. Cost were expressed in € 2012 and
include drug and administration costs, and drug-related adverse events manage-
ment cost. This analysis was performed taking into account the Spanish National
Health System’s perspective. Patient data on progression-free and overall survival
were obtained from the EURTAC study. Probabilistic sensitivity analyses were con-
ducted to incorporate parameter uncertainties.RESULTS: Erlotinib treated patients
achieved a mean of 2.161 LYG compared to 1.555 LYG in patients receiving chemo-
therapy. Total mean treatment cost with erlotinib and chemotherapy was €22,458
and €5,335 respectively. The incremental cost-effectiveness ratio (ICER) per LYG
was €28,261. Since erlotinib treatment is prolonged until disease progression and
chemotherapy is stopped at 4 cycles, treatment duration is one of the cost-driver of
the model. CONCLUSIONS: Erlotinib treatment of NSCLC patients with activating
EGFR mutations is associated with an increased life expectancy and is a cost-
effective therapeutic option in Spain.
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OBJECTIVES: Hormone refractory prostate cancer has generally poor prognosis
with an expected median survival of approximately 12 months. Cabazitaxel is an
antineoplastic agent, recommended by NCCN guidelines in metastatic, hormone-
resistant patients, after docetaxel therapy. Available alternatives are: mitoxan-
trone, a second docetaxel-containing regimen and other rescue chemotherapies.
Although in Italy an official cost-effectiveness threshold value is not identified, the
Italian Association of Health Economics (AIES) identifies a range from € 25.000 to €
40.000/QALY or LYG. The objective of the study is to evaluate the cost-effectiveness
of cabazitaxel versus mitoxantrone in the Regional Health Service (RHS).
METHODS: Survival data from the TROPIC trial were used to calculate the Incre-
mental cost-effectiveness Ratio (ICER). The maximum hospital wholesale price
allowable for Cabazitaxel and regional tender price for mitoxantrone were used to
calculate costs of treatment (e.g. 6 cycles every 3 weeks). The perspective was
RHS’s. It was decided to develop a conservative analysis and to quantify only the
cost of drugs, as other direct costs (i.e. staff, premedication, managing adverse
events) were not quantifiable or highly variable. The cost of drug administration
was not considered, since it was the same for both drugs. RESULTS: Therapy with
cabazitaxel versus mitoxantrone leads to an increase of the survival ( 0.20/years)
and an increase of costs ( €18.785). The ICER is € 93.925/LYG. CONCLUSIONS: The
estimated ICER is similar to what is shown in the more complete analysis of the
National Institute for Health and Clinical Excellence and the Scottish Medicines
Consortium. Moreover, the analysis was conservative because cabazitaxel showed
more adverse events than mitoxantrone. If quantified, the ICER would have been
higher. The Pharmacy and Therapeutic Committee of the Veneto Region expressed
a negative opinion to the inclusion of the drug in the Regional Drug Hospital For-
mulary.
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OBJECTIVES: The purpose of this study was to explore the cost-effectiveness of
abiraterone acetate (abiraterone) vs. cabazitaxel in metastatic castration-resistant
prostate cancer (mCRPC) patients who progressed after docetaxel from the Greek
health care perspective. METHODS: As no head-to-head trial data were available
for abiraterone versus cabazitaxel, an indirect cost-effectiveness model was devel-
oped using clinical data (progression free survival (PFS), overall survival (OS), ad-
verse events (AEs)) from the pivotal Phase 3 clinical trials COU-AA-301 (abiraterone)
and TROPIC (cabazitaxel). The basic assumption in the model was that both com-
parator arms in the trials were ‘palliative’ and therefore equivalent. Resource use,
particularly for the management of AEs, was estimated based on data from Alex-
andra University Hospital in Athens. For validation purposes, a secondary analysis
was conducted using UK resource use data. Both analyses used local 2012 costs,
undiscounted. Costs of hospitalisation, day hospital visits, drug administration
and laboratory tests were taken from officially published public tariffs. Drug acqui-
sition costs came from the latest Price Bulletins. Since abiraterone and cabazitaxel
are not yet marketed in Greece, respective prices were estimated based on avail-
able EU prices in April 2012. Calculations were based on the median treatment
duration for each agent. RESULTS: Total treatment cost was lower for abiraterone
(€25.847) compared to cabazitaxel (€26.648). Higher drug acquisition costs for abi-
raterone (€24.899 vs. €23.886 for cabazitaxel) were offset by lower administration
costs (€844 vs. €2.292) and lower AE management costs (€104 vs. €470). The total
treatment costs of abiraterone were €12.924 and €5.619 per incremental month of
PFS and OS compared to palliative care, respectively; treatment costs for cabazi-
taxel were €19.034 and €11.103 per additional month of PFS and OS against pallia-
tive care, respectively. Results were validated by the secondary analysis.
CONCLUSIONS: Abiraterone appears to be a potentially cost-effective option com-
pared with cabazitaxel in the Greek health care setting.
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OBJECTIVES: To perform an analysis, from a public financing viewpoint, of the
economic impact and efficiency of the Oncotype DX (ODX) assay as a guide to
providing chemotherapy to women with early breast cancer compared to guiding
this decision using the Adjuvant! Online (AO) prognostic index.METHODS:Markov
model was constructed to assess three alternatives: provision of chemotherapy to
women with a high risk recurrence score (RS) (i.e., 30) with ODX, to women with
an intermediate/high risk score (RS 18) and to those as indicated by the AO. For
the base case, a price of €3200 was set for ODX plus €236.12 for treatment with
tamoxifen for 6 months, plus €3490.50 for six cycles of chemotherapy. RESULTS:
Mean cost associated with AO to guide the provision of chemotherapy was €8994.02
per patient, with ODX RS 30 as a guide was €11,521.56, and for RS 18 it was
€12,070.03. The incremental cost effectiveness ratio for ODX RS 30 compared to
AO was €9659.28 per QALY; for ODX RS 18 was €7105.80. When treatment was
guided by AO, a mean of 16.80 QALYs were obtained per patient, ODX was associ-
ated with a mean 17.06 QALY with an RS of 30 and 17.13 QALY per with an RS of
18. In probablistic sensitivity analysis, assuming a willingness to pay of €10,000/
QALY, providing chemotherapy to patients with an ODX RS of18 became the best
alternative. Probability of this being the best choice was 60% for a willingness to pay
of €20,000 /QALY and 70% for €30,000 /QALY. CONCLUSIONS: Compared to guiding
the provision of chemotherapy with AO, the ODX would appear to be cost-effective.
In the Spanish setting, for a willingness to pay €30,000/QALY, the best option would
appear to be to prescribe chemotherapy for patients with ODX RS of 18.
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OBJECTIVES: To estimate the cost-effectiveness of once-daily abiraterone acetate
(AA) plus prednisolone for the treatment of advanced metastatic castration-resis-
tant prostate cancer (mCRPC) after failure of taxane-based chemotherapy such as
docetaxel, under the Brazilian Private Health System perspective. METHODS: A
cost-effectiveness analysis was developed based in a Markov model to simulate the
disease progression and patient mortality. A systematic revision of the literature
was developed over the efficacy and safety of the use of AA and cabazitaxel (C),
both combined with prednisolone (P), in patients diagnosed with advanced mCRPC.
Efficacy data is informed by the Phase III trials (C  P versus mitoxantrone (M)  P
and AA  P versus P). Data is combined and adjusted via a mixed treatment com-
parison network meta-analysis to determine the relative efficacy of each compar-
ator front a controlled therapy used as efficacy reference for the clinical tests (HR
for overall survival (OS): CP vs M  0.703 (IC95%: 0.59-0.83); AA  P vs P  0.649
(IC95%: 0.543-0.768)). It was assumed that M  P is equal to P alone. The costs and
consequences of the disease treatment were computed for each treatment alter-
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native. Only direct medical costs were considered. Costs and outcomes were dis-
counted at 5% yearly. The outcomes considered were life years (LY) and quality
adjusted life years (QALY). RESULTS: The incremental cost-effectiveness analysis
demonstrated that AA is the most economically attractive medication. When the
incremental cost-effectiveness ratio (ICER) for LY and QALY gained was evaluated,
AA was dominant with regards to C, being more effective (LY: 1.3559 vs 1.2895;
QALY: 0.7977 vs 0.7329) with lower costs (R$79,974 vs R$90,025).CONCLUSIONS:AA
is the best therapeutic option, with the best cost-effectiveness ratio, versus C for
the treatment of patients diagnosed with advanced mCRPC under Brazilian private
perspective.
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OBJECTIVES: To identify the cost effectiveness ratio of Vemurafenib in the treat-
ment of patients of the public health care institutions in Mexico, with BRAF positive
mutation (BRFAF ) metastatic or advanced melanoma, compared with dacarba-
zina and temozolomide. METHODS: A Markov model was developed with monthly
cycles, with 4 health states: clinical benefit, stable disease, disease progression and
death, considering the adverse events as transitory stages, during a 5 year time
horizon. A cost effectiveness analysis was developed, where the transition proba-
bilities between the different health’s states considered, are the basis to estimate
how many life years (LY) the patients will achieve with the different treatment
alternatives. The costing method used in this study is the direct medical costs,
expressed in US dollars. RESULTS: In the pharmacoeconomic analysis, Vemu-
rafenib was the most effective treatment producing a mean of 2.15 LY per patient
during the 5 year time horizon, 1.17 additional LY to those produced by dacarbazine
(.98 LY) or temozolomide (0.98 LY). This shows that Vemurafenib is the most effec-
tive alternative for this patient due the effectiveness is 2.2 times higher compared
to dacarbazine and temozolomide. CONCLUSIONS: Given the current worldwide
discussion regarding the cost-effectiveness (CE) of orphan drugs, is considered
necessary to evaluate these drugs under a different criteria that those used for
drugs that are not orphans. So patients, who have rare and deadly diseases, can
have the opportunity to live longer and better.
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OBJECTIVES: To perform a cost-effectiveness analysis based on markers of re-
sponse/resistance including biological therapies available in Spain for metastasic
colorectal cancer (mCRC). METHODS: Incremental cost-effectiveness ratio (ICER)
per life-year gained (LYG) and progression-free year gained were calculated based
on predictive markers for mCRC. Efficacy data include randomized trials (RT) that
guided on-label uses of bevacizumab and cetuximab. Control arms from these
trials were used as reference scenario. Markers of clinical benefit (biological &
radiological) were included. Toxicity as predictor of efficacy was excluded for any
therapy. Prices for drugs in Spain were assumed to represent the best-value for
each drug including all possibilities to reduce pharmacy costs. For 1st line, median
duration of therapy reported by RT was used to calculate the final budget. 70kg and
1.7 m were used as reference for patients dose calculations. If accessible, HR for PFS
and OS were used instead of medians. RESULTS: K-Ras status and early response
measured by computed tomography at 8 weeks were used as predictors of resis-
tance and increased efficacy for cetuximab-based combinations. We have not iden-
tified any predictor marker for other drugs from RT. In this regard,
FOLFIRIcetuximab combination obtained an ICER below the widely-proposed
Spanish threshold of 30,000 € per LYG if patients harbored wild type (wt) K-Ras
tumors and evidenced an objective response at 8 weeks. Other ICERs for different
schedules were too distant from this limit. Multivariate analysis confirmed the
robustness of results. CONCLUSIONS: First-line FOLFIRIcetuximab therapy for wt
K-Ras patients that get an objective response measured by CT at 8 weeks is the only
cost- effective therapy option for mCRC below usual health economics thresholds
for Spain. Our results are critical to design cost-effectiveness based clinical guide-
lines for mCRC that will contribute to financial sustainability of public health sys-
tem in Spain.
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OBJECTIVES: To conduct a cost effectiveness analysis (CEA) comparing 3.75 mg
1-month (1M), 11.25 mg 3-month (3M) and 30 mg 6-month (6M) leuprorelin acetate
formulations (LAF) in patients with advanced prostate cancer (APC) in Switzerland.
METHODS: A CEA was performed from the payer perspective using a decision-tree
model. Total treatment costs per patient per year and cost-effectiveness ratios
(CER) were calculated. Clinical efficacy and safety data (serum testosterone
50ng/dl and adverse drug reactions /ADRs/) for LAF were obtained from random-
ized trials. Direct medical costs (drug, physician consultation and drug adminis-
tration, and ADRs), reported as 2011 in Swiss Francs (CHF), were obtained from a
Swiss health care database (Tarmed) and doctor interviews. We assumed a patient
would visit the physician’s office a minimum of 12, 4 and 2 times/year when treated
with 1M, 3M and 6M LAF, respectively. The modeled annual costs were extrapo-
lated to the median survival time (3.1 years) of a patient with APC. One and two-
way sensitivity analysis was conducted to check robustness of the model.
RESULTS: In Switzerland, the annual cost associated with 6M LAF (CHF 3,320) was
lower than that associated with 3M (CHF 4,411) and 1M (CHF 5,672) LAF. The lifetime
costs of treatment with 1M, 3M and 6M LAF were CHF 16,349, CHF 12,715 and CHF
9,664, respectively (Discount rate3%). Annual cost savings associated with the 6M
formulation were 41% and 24% over the 1M and 3M formulations, respectively. 1M
and 3M LAF were dominated with higher overall costs and lower effectiveness
compared to the 6M formulation (CERCHF 5,154/effectiveness). Sensitivity anal-
ysis confirmed the robustness of the results. CONCLUSIONS: Results suggest 6M
LAF as a cost-effective strategy for treating patients with APC. Dosing frequency,
reduction of possible local side reactions and number of outpatient visits could be
potential factors in optimizing drug-related treatment costs for APC.
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OBJECTIVES: To compare, from a Dutch health care payer perspective, bendamus-
tine against chlorambucil. The latter is the current first line treatment for CLL
patients with Binet stage B or C for whom fludarabine combination therapy is not
appropriate. METHODS: A Markov model to reflect the treatment sequence of pa-
tients with CLL in the Netherlands was developed in Treeage pro suite 2009 linked
to Excel 2007. Three treatment lines were modelled before patients reached best
supportive care. This treatment path was supported by a Dutch CLL expert panel.
Transition probabilities were derived from clinical trials, the expert panel and
Dutch mortality statistics. Health care resource utilisation was estimated for each
health state using clinical guidelines and the expert panel. Model outcomes were
life years (LY), quality-adjusted life years (QALYs), progression free life years (PFLY),
and total CLL related health care costs (2011 values). The model time horizon was
10 years and monthly cycles were used. Annual discounting of 4%/1,5% was applied
on costs and effects, respectively. RESULTS: The analysis showed that patients
with bendamustine and chlorambucil as first line treatment generated 3.77 and
2.21 QALYs, respectively. The total average costs amounted to €79,328 for benda-
mustine, and €67,172 for chlorambucil. The incremental cost effectiveness ratio
(ICER) of bendamustine compared to chlorambucil was €7,809 per QALY gained.
The incremental cost per LY and PFLY gained were €7,374 and €6,908. The cost-
effectiveness acceptability curve indicated that the probability that bendamustine
was cost-effective approximated 95% at a threshold of €20,000 per QALY.
CONCLUSIONS: Bendamustine compared to chlorambucil, in previously untreated
Binet B or C CLL patients for whom fludarabine combination therapy is not appro-
priate, generated an ICER of €7,809 per QALY gained. This indicated that benda-
mustine is cost-effective as first line treatment for CLL in the Netherlands.
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OBJECTIVES: Previous analyses have projected the health and economic impact of
Herceptin® (trastuzumab) in HER2-positive (HER2) breast cancer over the product
life cycle in the US and major EU markets from a payer perspective. The objective of
this analysis is to project the overall product life cycle cost-effectiveness of trastu-
zumab in HER2 breast cancer treatment in Portugal, a relatively small (10.6 mil-
lion inhabitants), lower income EU country, considering the societal perspective.
METHODS: Using a product life cycle modeling approach, the projected life cycle
(“dynamic”) incremental cost-utility ratio (ICUR) was estimated for the period 2000
to 2020. The model combines projected “static” ICURs for trastuzumab in early
(eBC) and metastatic (mBC) HER2 BC based on the literature with epidemiological
projections of annual HER2 BC disease incidence and the utilization of trastu-
zumab in Portugal over this 21-year period. The major societal saving is reduced
work loss for women with eBC who receive trastuzumab. The dynamic model
considers both a payer and societal perspective over a lifetime horizon. All costs (in
2012 Euros) and outcomes are discounted at 3.0% to the year 2000. RESULTS: The
model projects that over the 21-year period, 10,900 women would receive trastu-
zumab treatment for eBC, and 5,200 women for mBC. Given the respective ICURs
from a payer perspective for eBC (11,000€ per quality adjusted life year (QALY)) and
for mBC (43,000€ per QALY), the overall dynamic ICUR is approximately 15,000€ per
QALY from payer perspective. Taking a societal perspective, this is projected to be
reduced by at least 15%. CONCLUSIONS: Taking a dynamic—and societal—life cy-
cle perspective, in the case of Portugal, over 16,000 QALYs are projected to be
gained through the year 2020 at a very favorable ICUR of less than 13,000€per QALY.
Viewed over the product life cycle, trastuzumab for breast cancer would be consid-
ered cost-effective in Portugal.
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